CDK4/6 inhibitors prolong OS

被引：0
|
作者：
David Killock
机构：
[1] Nature Reviews Clinical Oncology,
来源：
Nature Reviews Clinical Oncology | 2019年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：722 / 722
相关论文
共 50 条
  • [41] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [42] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [43] CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics
    Lai, Fobao
    Fang, Yingbing
    Cheng, Cong
    Zhong, Xuejing
    Zheng, Wanrong
    Lan, Shiqian
    Peng, Quanshui
    Cai, Xiumei
    Cao, Tiantian
    Zhong, Chengqian
    Gao, Yuzhen
    CURRENT MEDICINAL CHEMISTRY, 2025, 32 (02) : 343 - 358
  • [44] Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6
    Wu, Xuewei
    Yang, Xiaobao
    Xiong, Yan
    Li, Ruitong
    Ito, Takahiro
    Ahmed, Tamer
    Karoulia, Zoi
    Adamopoulos, Christos
    Wang, Hong
    Wang, Li
    Xie, Ling
    Ueberheide, Beatrix
    Aaronson, Stuart
    Chen, Xian
    Sellers, William
    Buchanan, Sean
    Jin, Jian
    Poulikakos, Poulikos I.
    CANCER RESEARCH, 2021, 81 (13)
  • [45] Different expression of CDK4 and CDK6 among B-cell non-Hodgkin lymphomas as a marker of sensitivity to CDK4/6 inhibitors
    Vesela, D.
    Kupcova, K.
    Klener, P.
    Havranek, O.
    Krystof, V.
    Jorda, R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S78 - S78
  • [46] Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
    Kong, Yan
    Sheng, Xinan
    Wu, Xiaowen
    Yan, Junya
    Ma, Meng
    Yu, Jiayi
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Dai, Jie
    Li, Yiqian
    Yu, Huan
    Xu, Tianxiao
    Tang, Huan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6946 - 6957
  • [47] Can CDK4/6 inhibitors cause fatal lung injury?
    Jazieh, Khalid A.
    Budd, G. Thomas
    Dalpiaz, Nancy
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 917 - 919
  • [48] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
    Marie Robert
    Jean-Sébastien Frenel
    Emmanuelle Bourbouloux
    Dominique Berton Rigaud
    Anne Patsouris
    Paule Augereau
    Carole Gourmelon
    Mario Campone
    Drugs, 2018, 78 : 1353 - 1362
  • [49] Activity of CDK4/6 inhibitors in translocation renal cell carcinoma
    Gupta, S.
    Khanna, P.
    Saad, E.
    Saliby, R.
    Li, J.
    Li, B.
    Sadagopan, A.
    Xu, Q.
    Bakouny, Z.
    Lee, G. S. Mary
    Choueiri, T. K.
    Viswanathan, S. R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S23 - S23
  • [50] CDK4/6 inhibitors: a brief overview and prospective research directions
    Adon, Tenzin
    Shanmugarajan, Dhivya
    Kumar, Honnavalli Yogish
    RSC ADVANCES, 2021, 11 (47) : 29227 - 29246
12345